Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic her-2/neu mice.
Female transgenic FVB/N mice carrying the breast cancer gene HER-2/neu received epithalon (Ala-Glu-Asp-Gly) in a dose of 1 mg subcutaneously 5 times a week to from the 2nd month of life to death. Epithalon prolonged the average and maximum lifetimes of mice by 13.5 (p<0.05) and 13.9%, respectively. The peptide prolonged the average lifetime of animals without neoplasms (by 34.2%, p<0.05). Epithalon decelerated the development of age-related disturbances in reproductive activity and suppressed the formation of neoplasms. The peptide decreased the incidence of breast adenocarcinomas, lungs metastases (by 1.6 times, p<0.05), and multiple tumors (by 2 times). Epithalon 3.7-fold increased the number of mice without breast tumors (p<0.05), while the number of animals with 6 or more breast tumors decreased by 3 times (p<0.05). Epithalon prolonged the lifetime of mice with breast tumors by 1.4 times (p<0.05). These results indicate that Epithalon possesses geroprotective activity and inhibits breast carcinogenesis in transgenic mice, which is probably related to suppression of HER-2/neu expression.
Anisimov
V N
VN
Max Planck Institute for demographic Research of Society, Rostock, Germany.
Khavinson
V Kh
VKh
Alimova
I N
IN
Semchenko
A V
AV
Yashin
A I
AI
D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology*; D000375:Aging / Q000187:drug effects*; D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D051379:Mice; D008822:Mice, Transgenic; D009842:Oligopeptides / Q000494:pharmacology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
D009842:Oligopeptides; D018719:Erb-b2 Receptor Tyrosine Kinases; C421253:alanyl-glutamyl-aspartyl-glycine